title: Evaluation of the effect of pyrrolidine dithiocarbamate in suppressing inflammation in mice with dextran sodium sulfate-induced colitis.
abstract: OBJECTIVE
  To evaluate the effect of pyrrolidine dithio-carbamate (PDTC; an NF-kappaB inhibitor) administered at low (50 mg/kg) and high (100 mg/kg) doses in suppressing colitis in mice with dextran sodium sulfate (DSS)-induced colitis.
  
  
  METHODS
  Mice were divided into a DSS-untreated group (normal group), DSS-treated control group, DSS+PDTC-treated group I (low-dose group), and DSS+PDTC-treated group II (high-dose group). In each group, the disease activity index score (DAI score), intestinal length, histological score, and the levels of activated NF-kappaB and inflammatory cytokines (IL-1beta and TNF-alpha) in tissue were measured.
  
  
  RESULTS
  The DSS+PDTC-treated group II exhibited suppression of shortening of intestinal length and reduction of DAI score. Activated NF-kappaB level and IL-1beta and TNF-alpha levels were significantly lower in DSS+PDTC-treated group II.
  
  
  CONCLUSIONS
  These findings suggest that PDTC is useful for the treatment of ulcerative colitis.
authors.affiliation: Department of Gastroenterology, Fujita Health University, Toyoake, Aichi 470-1192, Japan. ihirata@fujita-hu.ac.jp
authors.forename: Ichiro
authors.initials: I
authors.lastname: Hirata
authors.forename: Shingo
authors.initials: S
authors.lastname: Yasumoto
authors.forename: Ken
authors.initials: K
authors.lastname: Toshina
authors.forename: Takuya
authors.initials: T
authors.lastname: Inoue
authors.forename: Takashi
authors.initials: T
authors.lastname: Nishikawa
authors.forename: Naoko
authors.initials: N
authors.lastname: Murano
authors.forename: Mitsuyuki
authors.initials: M
authors.lastname: Murano
authors.forename: Fang-Yu
authors.initials: FY
authors.lastname: Wang
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Katsu
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D003106:Colon / Q000378:metabolism / Q000473:pathology; D016264:Dextran Sulfate; D004195:Disease Models, Animal; D005260:Female; D007202:Indicators and Reagents; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D007274:Injections, Intraperitoneal; D053583:Interleukin-1beta / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D016328:NF-kappa B / Q000378:metabolism; D011759:Pyrrolidines / Q000008:administration & dosage / Q000494:pharmacology*; D012720:Severity of Illness Index; D013859:Thiocarbamates / Q000008:administration & dosage / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000975:Antioxidants; D007202:Indicators and Reagents; D053583:Interleukin-1beta; D016328:NF-kappa B; D011759:Pyrrolidines; D013859:Thiocarbamates; D014409:Tumor Necrosis Factor-alpha; C020972:pyrrolidine dithiocarbamic acid; D016264:Dextran Sulfate